Search - tctmd.com

Displaying 481 - 500 of 883

Sort: Relevancy | Date

Presentation The Structural Heart Disease Summit 2018

Patient Selection: Making the Subjective Objective (Frailty, Depression)

Presenter: Marian C. Hawkey

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Diagnostic Evaluation: Historical Requirements and Emerging Evidence (LHC, TTE, TEE, CTA, Carotid US, PFTs)

Presenter: Kim Guibone

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Pharmacotherapy Considerations Trials and Practical Clinical Recommendations

Presenter: George D. Dangas

June 21, 2018

Presentation EuroPCR 2018

Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-controlled SPYRAL HTN-ON MED Trial

Presenter: David E. Kandzari

May 23, 2018

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

Presentation EAS 2018

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

Presentation EAS 2018

Stress, Behavior and Cardiovascular Disease

Presenter: Viola Vaccarino

May 06, 2018

Presentation ECHO 2018

Echocardiographic Approach To Congenital Heart Disease: The Postoperative Adult

Presenter: Karen Stout

April 20, 2018

Presentation ECHO 2018

Evaluation of Pregnant Patients with Heart Disease

Presenter: Karen Stout

April 20, 2018

Presentation ECHO 2018

Diastology Sucks

Presenter: Gerard P. Aurigemma

April 20, 2018

Presentation ECHO 2018

Pulmonary Hypertension and the Role of Echocardiography

Presenter: Linda D. Gillam

April 19, 2018

Presentation CIT 2018

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

Presenter: Ran Kornowski

March 23, 2018

Presentation ACC 2018

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Presenter: Brendan M. Everett

March 12, 2018

Presentation ACC 2018

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Presenter: Diego Ardissino

March 12, 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticouagulants

Presentation ACC 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Presenter: Steve Deitelzweig

March 12, 2018

Presentation ACC 2018

Results of the SWAP (Switching Antiplatelet Therapy) - 4 Study

Presenter: Francesco Franchi

March 11, 2018

Presentation ACC 2018

Uptake and Utilization of Drug-Eluting Bioresorbable Vascular Scaffolds: A CathPCI Registry Study

Presenter: Ajay J. Kirtane

March 11, 2018

Presentation ACC 2018

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

Presenter: William B. White

March 11, 2018

Presentation ACC 2018

Hospital Readmission Following Perioperative Myocardial Infarction Associated with Non-Cardiac Surgery

Presenter: Nathaniel R. Smilowitz

March 11, 2018

Presentation ACC 2018

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Presenter: Philippe Gabriel Steg

March 10, 2018

Advertisement

Patient Selection: Making the Subjective Objective (Frailty, Depression)

Diagnostic Evaluation: Historical Requirements and Emerging Evidence (LHC, TTE, TEE, CTA, Carotid US, PFTs)

Pharmacotherapy Considerations Trials and Practical Clinical Recommendations

Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-controlled SPYRAL HTN-ON MED Trial

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Stress, Behavior and Cardiovascular Disease

Echocardiographic Approach To Congenital Heart Disease: The Postoperative Adult

Evaluation of Pregnant Patients with Heart Disease

Diastology Sucks

Pulmonary Hypertension and the Role of Echocardiography

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Results of the SWAP (Switching Antiplatelet Therapy) - 4 Study

Uptake and Utilization of Drug-Eluting Bioresorbable Vascular Scaffolds: A CathPCI Registry Study

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

Hospital Readmission Following Perioperative Myocardial Infarction Associated with Non-Cardiac Surgery

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content